MGUS/SMM Trials | Myeloma Trials

NCT05288062: Phase 2: Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) + Dex

NCT05288062: Phase 2: Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug...

NCT05136807: Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies

NCT05136807: Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies NCT05136807: Quality of Life in Patients With...

The PCROWD Study invites people with precursor conditions to Share samples a few times each year

The PCROWD Study invites people with precursor conditions to Share samples a few times each year when they are collected as part of...

NCT05014646: Phase 2: Leflunomide for High-Risk Smoldering MM in African-Am. & European-Am. Patients

NCT05014646: Phase 2: Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American...

NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM)

PRISM High Risk Smoldering Multiple Myeloma NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM) The purpose of this research study...

NCT04776395: Phase 2: Iberdomide Alone or in Combination With Dex for Intermediate/High-Risk SMM

NCT04776395 Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple...

NCT04850846: Phase 2: Investigation of Metformin for the Prevention of Progression of Precursor MM

NCT04850846: Phase 2: Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma Investigation of...

NCT04920084: A Study of a Plant-Based Diet in People With MGUS / Smoldering Myeloma - NUTRIVENTION

NUTRIVENTION Study NCT04920084: A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or...

NCT04512235: Phase 3: To Evaluate Effectiveness & Safety of CAEL-101 in Stage IIIa AL Amyloidosis

CAEL-101 Amy NCT04512235: Phase 3: A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL...